RT @brootmcq: The authors calculated a 1:2 mo PFS to OS benefit when our ICER review on PARPs calculated a 1:0.5 benefit. They didn’t cite…
The authors calculated a 1:2 mo PFS to OS benefit when our ICER review on PARPs calculated a 1:0.5 benefit. They didn’t cite our report. Hopeful patients get this benefit but no one can confirm this relationship. Maybe a letter to @PECjournal? 🤔 https://
Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States. https://t.co/V4kI7WnwgB
RT @HealthEconBot: #HealthEconJA Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Tr…
#HealthEconJA Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States https://t.co/GceUDj8mOf